Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat and Gemtuzumab Ozogamicin for Older Patients With Untreated AML
NCT00673153Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Mar 2008
- Primary completion
- Aug 2010
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Covalent Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat, gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Fred Hutchinson Cancer Center. Started Mar 2008; status: terminated.
02
Drugs
vorinostatgemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00673153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00673153.